Professional Documents
Culture Documents
Objectives
After completion of this module, the physician will be able to:
1. 2.
3.
4.
Identify women at risk for cervix cancer. Describe the probable etiologic factors that contribute to the development of cervix cancer. Explain why cervix cancer is suitable for screening. Describe the screening procedure for cervix cancer.
Objectives (continued)
After completion of this module, the physician will be able to:
5.
6.
7.
Describe the reporting system(s) used for Pap smear. Describe the recommendations for evaluation and follow-up of women with abnormal Pap test results. Encourage women to be screened for cervix cancer.
It is the second most common cancer site in women worldwide. It is the most common cancer site and cause of cancer death in women in many developing countries. Women with cervical cancer die at a younger age than those with any other non-childhood cancer.
Black White
Source: Herrero, Rolando. Journal of the National Cancer Institute Monographs, No. 21:3, 1996.
25-29
35-39
Age at diagnosis
45-49
55-59
65-69
75-79
85+
Black White
Year of death
Source: Herrero, Rolando. Journal of the National Cancer Institute Monographs, No. 21:3, 1996
1980
1985
1990
1995
No prior smear screening History of cervical dysplasia or genital warts Young age at first coitus Multiple sex partners High-risk male partner (e.g., multiple female partners) Sexually transmitted diseases Cigarette smoking Increasing age
Its a common disease. It has serious consequences. It has a detectable, asymptomatic phase. Early detection and treatment decrease morbidity and mortality. The screening test is acceptable to patients, safe, and affordable.
Sensitivity: 50-70% Specificity: 30-50% Inexpensive Minimal risk and discomfort to the patient
Inadequate smear technique/sample Improper laboratory preparation/evaluation Failure of health care provider to properly interpret and manage an abnormal result Failure of the patient to comply with recommendations for evaluation and treatment Invasive cancer at the time of initial evaluation
How often should Pap tests be performed? Should a woman who has had a hysterectomy continue to have periodic Pap tests? When should the Pap test be repeated if endocervical cells are not present? Should Pap tests be performed in patients older than age 60?
Statement about the adequacy of the specimen General categorization of the diagnosis Descriptive diagnosis
Infection Reactive and reparative changes Epithelial cell abnormalities Nonepithelial malignant neoplasm (specify) Hormonal evaluation (vaginal smear only) Other
Atypical squamous cells of undetermined significance (recommended follow-up specified) Squamous intraepithelial lesion (SIL)
Low grade SIL: HPV changes and/or CIN I High grade SIL: CIN II, CIN III, or CIS
Adenocarcinoma (probable site of origin specified) Other epithelial malignant neoplasm: specify
Identifies the area of abnormality for biopsy Defines the extent of the cervical lesion Delineates the areas of greatest abnormality
Biopsy lesion
Histological Confirmation
Excision
>90% >90%
Staging examination
Complete physical and pelvic examination Palpation of the lymph node-bearing areas Cystoscopy/proctoscopy for advanced cancers Radiograph of the chest IVP and barium enema or computerized tomography of pelvis and abdomen Surgery for selected Stage I lesions Radiation therapy for all others
Metastatic survey
Treatment planning
39%
Identify patients who should be screened Educate patients regarding the importance and timing of Pap smears Conduct Pap smears properly Follow up abnormal Pap smear results
Barriers to Screening
Embarrassment, unpleasantness Lack of knowledge of recommended screening interval Financial barriers Lack of knowledge concerning the importance of screening
Summary
Cervix cancer is highly preventable Pap smear screening Treatment of precursor lesions (dysplasia)
Follow-up of abnormal Pap smear results is critical Colposcopically-directed biopsies Histologic evaluation and correlation with the Pap smear Definitive therapy
Reading List
1. 2.
3.
4.
American College of Obstetricians and Gynecologists. Recommendations on Frequency of Pap Test Screening. ACOG Committee Opinion 152. Washington, DC: ACOG, 1995. Anderson GH, et al. Organisation and results of the cervical cytology screening programme in British Columbia, 1955-85, British Medical Journal (Clin Res Ed) 296(6627):975-8, 1988. Broder S. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda workshop. Journal of the American Medical Association 267:1892, 1992. Burack RC, et al. How reminders given to patients and physicians affected pap smear use in a health maintenance organization: results of a randomized controlled trail. Cancer 82(12):2391-400, 1998.
6.
7.
8.
9.
Creasman WT, et al. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. Am J Obstet Gynecol 178(1 Pt 1):625, 1998. Devesa SS, et al. Recent trends in cervix uteri cancer. Cancer Nov. 15; 64(10):2184-90, 1989. Eaker ED, et al. Cervical cancer screening among women with and without hysterectomies. Obstet Gynecol 91(4):551-5, 1998. Frame PS, et al. Determinants of cancer screening frequency; the example of screening for cervical cancer. J AM Board Fam Pract 11(2):87-95, 1998. Hopman EH, et al. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv 53(2):97-106, 1998.
12.
13.
Lobell M, et al. Barriers to cancer screening in MexicanAmerican women. Mayo Clin Proc 73(4):301-8, 1998. Ollayos CW. Update on the Papanicolaou smear: new issues for the 1990s. Mil Med 162(8):521-3, 1997. Paskett ED, et al. Clinic-based interventions to promote breast and cervical cancer screening. Prev Med 27(1):120-8, 1998. Peters RK, et al. Risk Factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. Journal of the National Cancer Institute 77(5):1063-77, 1986.
Breast Cancer (and in interactive CD-ROM) Cancer in Special Populations Colorectal Cancer Head and Neck Caner Lung Cancer Nutrition and Cancer Risk Reduction Prostate Cancer Skin Cancer Surveillance of Cancer Patients
To order these modules in spiral bound or 35mm slide format, contact POEP at POEP@texmed.org or call 800-880-1300, ext. 1672.
Evaluation
To obtain CME credit for this module, complete the online evaluation and return with $10 to TMA/POEP, 401 West 15th Street, Austin, TX 78701-1680. Return to POEP online CME